Miami Cancer Institute, a part of Baptist Health South Florida, has chosen RayStation as the treatment planning system for its new proton therapy facility, which will be the first in South Florida. The facility will serve a wider region, giving patients in Latin America and the Caribbean access to the benefits of proton therapy.
RayStation will be used for all proton treatment planning at Miami Cancer Institute and the installation will include advanced features such as deformable registration, dose accumulation and adaptive radiation therapy. The facility will also be one of the early adopters of the Plan Explorer tool in RayStation, which enables automatic generation of a large number of treatment plans for defined clinical goals and combinations of treatment techniques and machines.
The agreement includes both clinical and research licenses, and RayStation will provide a platform for groundbreaking research at Miami Cancer Institute. In addition, the facility will work with RaySearch Laboratories on beta testing of RayStation treatment planning with TomoTherapy and CyberKnife systems from Accuray (this functionality is not yet market cleared).
Minesh Mehta, M.D., deputy director and chief of radiation oncology at Miami Cancer Institute, says: “The proton therapy facility is truly starting to take form, with the cyclotron now in place and our treatment planning system selected. We are pleased to partner with RaySearch, which has a very successful track record in providing advanced technologies to cutting-edge centers such as ours. We anticipate a long relationship that will include the implementation of new technologies in the years to come.”
Johan Löf, CEO of RaySearch Laboratories, says: “We are excited to partner with Miami Cancer Institute on this proton project. The center will provide an important health service for cancer patients in the South Florida area and we look forward to working with the team to assure they have the tools needed to provide their patients with the best possible care.”
Marc Mlyn, President of RaySearch Americas, says: “In addition to the technologies that the Institute will be able to implement right away, there are great opportunities for future development and fast-tracking of new workflows that will benefit everyone.”
About proton therapy
Proton therapy is a cutting-edge radiation therapy technique that is growing in popularity worldwide. Its benefits include the ability to deliver maximum dose at a very precise depth in the body, with significantly less irradiation of healthy tissue.
About Miami Cancer Institute
Miami Cancer Institute is part of Baptist Health South Florida, the largest healthcare organization in the region. Scheduled for completion during 2016, the Institute will house all of Baptist Health South Florida’s cancer services under one roof. It will also provide a world-class research destination, with access to clinical trials and groundbreaking treatments.
About RayStation
RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.
About RaySearch
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch markets the RayStation treatment planning system to clinics all over the world. In addition, RaySearch’s products are distributed through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm, and the company is listed in the Mid Cap segment on NASDAQ OMX Stockholm.
For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00
johan.lof@raysearchlabs.com